Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPX-Survivac and cyclophosphamide in ovarian, fallopian tube, or peritoneal cancer
NCT03332576Phase 1Completed
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Aug 2013
- Primary completion
- Sep 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of maveropepimut-S in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 cohorts), sponsored by ImmunoVaccine Technologies Inc. Primary endpoint: Safety as measured by adverse event reporting at 11 months. Started Aug 2013; status: completed.
02
Drugs
maveropepimut-S
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03332576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332576.